| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 890.4 | 599.0 |
| Gross profit | 509.2 | 442.1 |
| Profit before tax | -46.2 | 12.2 |
| Net income | -33.0 | 15.8 |
| EPS (diluted, $ a share) | $-0.14 | $0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +48.6% |
|---|---|
| Gross margin | 57.2% |
| Operating margin | -7.4% |
10-Q filed with the SEC, NYSE: HIMS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Hims & Hers Health, Inc.: key numbers
- Share price
- $17.55Close, Nov 17
- Sector
- Industrial Applications and Services
- Industry
- Services-Offices & Clinics of Doctors of MedicineSIC 8011
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Hims & Hers Health, Inc.
All →Hims & Hers Health Earnings Call: Key Takeaways
HIMS reported 49% revenue growth but saw a sequential subscriber decline of 100,000, pivoting toward higher-margin branded assortments and international expansion while investing heavily in AI and supply chain infrastructure.
- Call
- Nov 9, 2026, 5:00 PM ET
Hims & Hers Health Leadership Change
Hims & Hers Health, Inc. increased its board size to ten and appointed Dr. Andrew Huberman as a director, effective November 4, 2026. Alongside his board role, Dr. Huberman entered into a brand marketing and advisory agreement worth $3.5 million annually, while his media company, Scicomm Media LLC, secured a $5 million annual podcast advertising contract.
- Counterparty
- Dr. Andrew Huberman
- Term
- through 2027 annual meeting
Hims & Hers Health Financial Results
Hims & Hers Health reported Q3 2026 revenue of $890.4 million, a 49% year-over-year increase driven by significant international growth and a 13% rise in subscribers to 2.8 million. The company reported a net loss of $33.0 million compared to a profit in the prior year, while tightening its full-year revenue guidance and reducing its Adjusted EBITDA outlook.
- Term
- Q3 2026
“In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.”
Andrew Dudum, co-founder and CEO
“In the third quarter, we continued to apply what we’ve learned to make deliberate strategic decisions to position Hims & Hers for durable, multi-year growth.”
Yemi Okupe, Chief Financial Officer
Hims & Hers Health CLO Soleil Boughton Sells $95.6K of Stock
Soleil Boughton, CLO, sold 3,462 shares of Hims & Hers Health, Inc. at $27.60 a share, worth $95.6K in total on Oct 28, 2026. Shares held after the trade: 293,886 (-1.2%).
- Value
- $95.6K
- Shares
- 3,462
- Price
- $27.60
- Role
- CLO
- Holding change
- -1.2%
- Trade date
- Oct 28, 2026
Hims & Hers Health CLO Soleil Boughton Sells $101K of Stock
Soleil Boughton, CLO, sold 3,461 shares of Hims & Hers Health, Inc. at $29.06 a share, worth $101K in total on Oct 14, 2026. Shares held after the trade: 297,348 (-1.2%).
- Value
- $101K
- Shares
- 3,461
- Price
- $29.06
- Role
- CLO
- Holding change
- -1.2%
- Trade date
- Oct 14, 2026
Hims & Hers Health Executive Compensation
Hims & Hers Health, Inc. appointed Jonathan M. Franklin as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026. Mr. Franklin's compensation package includes a $425,000 base salary, a $150,000 signing bonus, and $3,000,000 in restricted stock units. He succeeds Irene Becklund, who is transitioning to an advisory role through July 2027.